1st Oct 2009 07:00
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem today provides an update regarding the Company's share investment plan, details of which were announced on 13 July 2009.
As a result of the subscription for Partnership Shares and the award of Matching Shares, the executive Directors have each increased their beneficial interest in the Company by 330 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of July, August and September at prices of 358p, 325p and 340p respectively.
The current beneficial interests of the executive Directors are set out below:
Matthew Walls 6,394 (0.09%)
Dr Catherine Booth 980,749 (13.60%)
Dr Ged Brady 749 (0.01%)
Dr Jeffrey Moore 15,249 (0.21%)
John Rylands 190,647 (2.64%)
For further details please contact:
Epistem Plc
Matthew Walls, CEO +44 161 606 7258
Piper Jaffray Ltd.
Neil Mackison / Rupert Winckler +44 20 3142 8700
Related Shares:
Genedrive